Hudson Vegas Investment Spv, L Sells 50,000 Shares of P3 Health Partners (NASDAQ:PIII) Stock

P3 Health Partners Inc. (NASDAQ:PIII) major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of P3 Health Partners stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $16.48, for a total transaction of $824,000.00. Following the completion of the transaction, the insider directly owned 48,959 shares of the company’s stock, valued at approximately $806,844.32. This trade represents a 50.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

P3 Health Partners Price Performance

P3 Health Partners stock opened at $10.95 on Friday. The company’s 50-day moving average is $11.00 and its 200-day moving average is $6.60. The firm has a market capitalization of $79.28 million, a PE ratio of -0.33 and a beta of 1.63. P3 Health Partners Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $16.89.

P3 Health Partners (NASDAQ:PIII) last issued its earnings results on Monday, August 10th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.26. The firm had revenue of $386.38 million during the quarter, compared to analyst estimates of $377.80 million.

Institutional Trading of P3 Health Partners

A hedge fund recently bought a new stake in P3 Health Partners stock. Diversified Trust Co purchased a new stake in P3 Health Partners Inc. (NASDAQ:PIII) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 20,316 shares of the company’s stock, valued at approximately $63,000. Diversified Trust Co owned 0.28% of P3 Health Partners at the end of the most recent reporting period. Institutional investors and hedge funds own 7.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PIII. TD Cowen restated a “hold” rating and issued a $14.00 price target (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. UBS Group set a $14.00 price objective on shares of P3 Health Partners in a report on Friday, May 15th. Weiss Ratings raised shares of P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. Lake Street Capital restated a “buy” rating and set a $23.00 target price on shares of P3 Health Partners in a research note on Tuesday. Finally, Wall Street Zen raised shares of P3 Health Partners to a “hold” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $17.00.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.